Epstein Secrets

From: ' To: Lesley Groff Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:17:36 +0000 Lesley please forward to Jeffrey rs Rony

From: ' To: Lesley Groff Subject: Fwd: FOURIER: Significant LDL Reductio

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:18:31 +0000

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Sub

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

From: Lesley Groff To: "Dr. Rony + Catherine Shimony" Subject: Re: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:18:21 +0000 will d

From: Lesley Groff To: "Dr. Rony + Catherine Shimony" Subject: R

approximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events' Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a